Efficacy of human papillomavirus type 16/18 AS04-adjuvanted Vaccine in Japanese women aged 20 to 25 years

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 847-855

  Konno, Ryo ^a   Tamura, Shinobu ^b   Dobbelaere, Kurt ^c   Yoshikawa, Hiroyuki ^d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Development and Medical Affairs Division   (Japan)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cervical cancer; Efficacy; HPV 16 18 AS04Yadjuvanted vaccine; Human papillomavirus; Persistent infection

Indexed keywords

AIMMUGEN; HEPATITIS A VACCINE; HUMAN PAPILLOMAVIRUS TYPE 16 18 AS04 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HISTOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; IMMUNOGENICITY; INFECTION PREVENTION; JAPANESE; MULTICENTER STUDY; NORMAL HUMAN; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIROLOGY; VIRUS INFECTION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; JAPAN; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES; YOUNG ADULT;

EID: 77956839601     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181da2128     Document Type: Article

References (23)

1. Parkin D. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533Y543.
2. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: A review. Bull World Health Organ. 2007;85:719Y726.
3. Bosch FX, Qiao YL, Castellsague X. The epidemiology of human papillomavirus infection and its association with cervical cancer. Int J Gynaecol Obstet. 2006;94(suppl 1):S8YS21.
4. Stanley M. Prophylactic HPV vaccines: Prospects for eliminating ano-genital cancer. Br J Cancer. 2007;96: 1320Y1323.
5. Ministry of Health, Labour & Walfare. Vital Statistics of Japan. http://ganjoho.ncc.go.jp/professional/statistics/statistics.html. Accessed December 19, 2009.
6. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007;121:621Y632.
7. Onuki M, Matsumoto K, Satoh T, et al. Human papillomavirus infections among Japanese women: Age-related prevalence and type-specific risk for cervical cancer. Cancer Sci. 2009;100:1312Y1316.
8. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369: 2161Y2170.
9. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04Yadjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301Y314.
10. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364:1757Y1765.
11. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet. 2006;367:1247Y1255.
12. The GlaxoSmithkline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04Yadjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975Y1985.
13. Carvalho D, Roteli C, Teixeira J, et al. Immunogenicity and safety of the HPV-16/18 AS04Yadjuvanted vaccine up to 7.3 years. Presented at the 25th International Papillomavirus Conference and Clinical Workshop; May 8Y14, 2009; Malmö, Sweden.
14. Carvalho D, Roteli C, Teixeira J, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04Yadjuvanted vaccine (Cervarixi): Follow-up to 7.3 years. Presented at the 16th International Meeting of the European Society of Gynaecological Oncology; October 11Y14, 2009; Belgrade, Serbia.
15. David MP, Herck KV, Hardt K, et al. Long-term persistence of antiYHPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol. 2009;115:S1YS6.
16. Konno R, Dobbelaere KO, Godeaux OO, et al. Immunogenicity, reactogenicity and safety of human papillomavirus (HPV)-16/18 AS04Yadjuvanted vaccine in Japanese women: Interim analysis of a phase II double-blind, randomized controlled trial at Month 7. Int J Gynecol Cancer. 2009;19:905Y911.
17. Konno R, Tamura S, Dobbelaere KO, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04Yadjuvanted vaccine in Japanese women aged 20Y25 years: Interim analysis of a phase II double-blind, randomized controlled trial. Int J Gynecol Cancer. 2010;20:404Y410.
18. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol. 2008;168: 123Y137.
19. World Health Organization Guidelines. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virusYlike particle vaccines. World Health Organization; Geneva, Switzerland, 2006:06.2050.
20. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04Yadjuvanted prophylactic cervical cancer vaccine in women aged 15Y55 years. Vaccine. 2009;27:581Y587.
21. Einstein M, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarixiand Gardasil\ human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18Y45 years. Hum Vaccine. 2009;5:705Y719.
22. Saijo Y, Sata F, Yamada H, et al. Ah receptor, CYP1A2, CYP1A2 and CYP1B1 gene polymorphism are not involved in the risk of recurrent pregnancy loss. Mol Hum Reprod. 2004;10:729Y733.
23. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum vaccines. 2009;5:332Y340.